The US Food and Drug Administration (FDA) on Friday issued a question-and-answer guidance to provide clarity to manufacturers on reporting post-approval changes to disposable manufacturing material.
Drugmakers looking to make a change to the drug substance manufacturing process during an application’s post-approval period should consult the US Food and Drug Administration’s (FDA) new draft ...
The popularity of GLP-1s have brought post-approval changes to New Drug Applications (NDAs) to centerstage. Recently, the FDA approved Wegovy in tablet form, offering an alternative to the injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results